Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
THB335 single dose · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| THB335 single dose | EXPERIMENTAL | Single dose of THB335 fasted |
| THB335 fasted and fed | EXPERIMENTAL | Single dose of THB335 fasted and then fed |
| THB335 multiple dose | EXPERIMENTAL | 14 days of multiple ascending doses of THB335 |
| Single dose placebo | PLACEBO_COMPARATOR | Single dose of placebo capsule, fasted |
| Fasted and fed placebo | PLACEBO_COMPARATOR | Single dose of placebo capsule fasted and then fed |
| Multiple dose placebo | PLACEBO_COMPARATOR | 14 days of multiple doses of placebo capsule |
| Name | Type | Description |
|---|---|---|
| THB335 single dose | DRUG | Single dose as oral capsule |
| Single dose placebo | DRUG | Single dose as oral capsule |
| THB335 fasted/fed | DRUG | Single dose fasted and fed as oral capsule |
| Placebo fasted/fed | DRUG | Single dose fasted and fed as oral capsule |
| THB335 multiple dose | DRUG | Multiple ascending doses oral capsule |
| Multiple dose placebo | DRUG | Multiple doses oral capsule |
Inclusion Criteria: * In good health, determined by no clinically significant findings from medical history, 12 lead electrocardiogram (ECG), vital sign measurements, and clinical laboratory evaluations * Males or females, of any race, between 18 and 65 years of age, inclusive. * Participants must ...
THB335 single dose is an investigational small molecule being developed by Third Harmonic Bio, Inc. for use in healthy participants. It is currently in Phase 1 clinical development, with one completed trial evaluating its safety and tolerability.
THB335 single dose is a small molecule, but its specific molecular target has not been disclosed in available information. The drug is being studied in a first-in-human trial to evaluate its effects in healthy participants.
THB335 single dose is being developed by Third Harmonic Bio, Inc., a biopharmaceutical company. The company is publicly traded under the ticker symbol THRD.
THB335 single dose is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and no active trials are currently listed.
THB335 single dose has been studied in one clinical trial, NCT06425861, titled 'A First in Human Trial Evaluating THB335 in Healthy Participants.' This Phase 1, randomized, double-blind, placebo-controlled trial enrolled 60 healthy adults in the United States and has been completed.
THB335 single dose is a formulation or dosing regimen of the investigational drug THB335. The single dose designation refers to the specific administration schedule being evaluated in clinical trials, while THB335 is the underlying drug candidate.